Effect of pneumococcal conjugate vaccine six years post-introduction on pneumococcal carriage in Ulaanbaatar, Mongolia.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
03 Aug 2024
Historique:
received: 25 03 2024
accepted: 24 07 2024
medline: 4 8 2024
pubmed: 4 8 2024
entrez: 3 8 2024
Statut: epublish

Résumé

Limited data from Asia are available on long-term effects of pneumococcal conjugate vaccine introduction on pneumococcal carriage. Here we assess the impact of 13-valent pneumococcal conjugate vaccine (PCV13) introduction on nasopharyngeal pneumococcal carriage prevalence, density and antimicrobial resistance. Cross-sectional carriage surveys were conducted pre-PCV13 (2015) and post-PCV13 introduction (2017 and 2022). Pneumococci were detected and quantified by real-time PCR from nasopharyngeal swabs. DNA microarray was used for molecular serotyping and to infer genetic lineage (Global Pneumococcal Sequence Cluster). The study included 1461 infants (5-8 weeks old) and 1489 toddlers (12-23 months old) enrolled from family health clinics. We show a reduction in PCV13 serotype carriage (with non-PCV13 serotype replacement) and a reduction in the proportion of samples containing resistance genes in toddlers six years post-PCV13 introduction. We observed an increase in pneumococcal nasopharyngeal density. Serotype 15 A, the most prevalent non-vaccine-serotype in 2022, was comprised predominantly of GPSC904;9. Reductions in PCV13 serotype carriage will likely result in pneumococcal disease reduction. It is important for ongoing surveillance to monitor serotype changes to potentially inform new vaccine development.

Identifiants

pubmed: 39097620
doi: 10.1038/s41467-024-50944-3
pii: 10.1038/s41467-024-50944-3
doi:

Substances chimiques

Pneumococcal Vaccines 0
13-valent pneumococcal vaccine 0
Vaccines, Conjugate 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6577

Subventions

Organisme : GAVI Alliance (Gavi)
ID : PP61690717A2

Informations de copyright

© 2024. The Author(s).

Références

Wahl, B. et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health 6, e744–e757 (2018).
doi: 10.1016/S2214-109X(18)30247-X pubmed: 29903376 pmcid: 6005122
International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub 2023. Available from: www.view-hub.org . (Accessed 03 April 2023).
Simell, B. et al. The fundamental link between pneumococcal carriage and disease. Exp. Rev. Vaccines 11, 841–855 (2012).
doi: 10.1586/erv.12.53
Davis, S. M., Deloria-Knoll, M., Kassa, H. T. & O’Brien, K. L. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 32, 133–145 (2013).
doi: 10.1016/j.vaccine.2013.05.005 pubmed: 23684824
Klugman, K. P. Herd protection induced by pneumococcal conjugate vaccine. Lancet Glob Health 2, e365–e366 (2014).
doi: 10.1016/S2214-109X(14)70241-4 pubmed: 25103373
Weinberger, D. M., Malley, R. & Lipsitch, M. Serotype replacement in disease after pneumococcal vaccination. Lancet 378, 1962–1973 (2011).
doi: 10.1016/S0140-6736(10)62225-8 pubmed: 21492929 pmcid: 3256741
Løchen, A., Truscott, J. E. & Croucher, N. J. Analysing pneumococcal invasiveness using Bayesian models of pathogen progression rates. PLoS Comput. Biol. 18, e1009389 (2022).
doi: 10.1371/journal.pcbi.1009389 pubmed: 35176026 pmcid: 8901055
Bertran, M. et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Lancet Infect. Dis. 24, 546–556 (2024).
doi: 10.1016/S1473-3099(23)00706-5 pubmed: 38310905
Mulholland, K. & Satzke, C. Serotype replacement after pneumococcal vaccination. Lancet 379, 1387 (2012).
doi: 10.1016/S0140-6736(12)60588-1 pubmed: 22500869
Weinberger, D. M. et al. Using pneumococcal carriage data to monitor postvaccination changes in invasive disease. Am J Epidemiol 178, 1488–1495 (2013).
doi: 10.1093/aje/kwt156 pubmed: 24013204 pmcid: 3813314
Chan, J. et al. Using pneumococcal carriage studies to monitor vaccine impact in low- and middle-income countries. Vaccine 37, 6299–6309 (2019).
doi: 10.1016/j.vaccine.2019.08.073 pubmed: 31500968
Shrestha, S. et al. Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study. Lancet Glob. Health 10, e1494–e1504 (2022).
doi: 10.1016/S2214-109X(22)00281-9 pubmed: 36113533
Dunne, E. M. et al. Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveys. Lancet Glob. Health 6, e1375–e1385 (2018).
doi: 10.1016/S2214-109X(18)30383-8 pubmed: 30420033 pmcid: 6231327
Satzke, C. et al. Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal conjugate vaccine. Vaccine 37, 296–305 (2019).
doi: 10.1016/j.vaccine.2018.10.077 pubmed: 30502068
Turner, P. et al. Impact of 13-valent Pneumococcal conjugate vaccine on colonization and invasive disease in Cambodian children. Clin. Infect Dis. 70, 1580–1588 (2020).
doi: 10.1093/cid/ciz481 pubmed: 31175819
Britton, K. J. et al. Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants. Vaccine 39, 5401–5409 (2021).
doi: 10.1016/j.vaccine.2021.07.085 pubmed: 34384633
von Mollendorf, C. et al. Pneumococcal carriage in children in Ulaanbaatar, Mongolia before and one year after the introduction of the 13-valent pneumococcal conjugate vaccine. Vaccine 37, 4068–4075 (2019).
doi: 10.1016/j.vaccine.2019.05.078
Jagne, I. et al. A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age. Vaccine 41, 3028–3037 (2023).
doi: 10.1016/j.vaccine.2023.03.063 pubmed: 37032228
Andrejko, K., Ratnasiri, B., Hausdorff, W. P., Laxminarayan, R. & Lewnard, J. A. Antimicrobial resistance in paediatric Streptococcus pneumoniae isolates amid global implementation of pneumococcal conjugate vaccines: a systematic review and meta-regression analysis. Lancet Microbe 2, e450–e460 (2021).
doi: 10.1016/S2666-5247(21)00064-1 pubmed: 34485957 pmcid: 8410609
CLSI. M100-ED29:2019 Performance Standards for Antimicrobial Susceptibility Testing 2019. Available from: https://clsi.org/standards/ .
World Health Organization, UNICEF. Immunization 2024 Mongolia country profile. Available from: https://www.who.int/publications/m/item/immunization-2024-mongolia-country-profile (Accessed 20 July 2024).
von Mollendorf C., et al. Changes in Pneumococcal Carriage in Hospitalised Children 2-59 Months of Age in Mongolia Following Pneumococcal Conjugate Vaccine Introduction. Available from: https://doi.org/10.2139/ssrn.4488943
Gladstone, R. A. et al. International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine 43, 338–346 (2019).
doi: 10.1016/j.ebiom.2019.04.021 pubmed: 31003929 pmcid: 6557916
van Hoek, A. J. et al. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine 32, 4349–4355 (2014).
doi: 10.1016/j.vaccine.2014.03.017 pubmed: 24657717
Swarthout, T. D. et al. High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi. Nat Commun 11, 2222 (2020).
doi: 10.1038/s41467-020-15786-9 pubmed: 32376860 pmcid: 7203201
Usuf, E. et al. Persistence of nasopharyngeal pneumococcal vaccine serotypes and increase of nonvaccine serotypes among vaccinated infants and their mothers 5 Years after introduction of pneumococcal conjugate vaccine 13 in The Gambia. Clin Infect Dis 68, 1512–1521 (2019).
doi: 10.1093/cid/ciy726 pubmed: 30165376
Hammitt, L. L. et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health 2, e397–e405 (2014).
doi: 10.1016/S2214-109X(14)70224-4 pubmed: 25103393 pmcid: 5628631
Yildirim, I. et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 29, 283–288 (2010).
doi: 10.1016/j.vaccine.2010.10.032 pubmed: 21029807 pmcid: 3139683
Rodgers, G. L., Whitney, C. G. & Klugman, K. P. Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe. The Journal of Infectious Diseases 224, S352–S359 (2021).
doi: 10.1093/infdis/jiaa535 pubmed: 34590137 pmcid: 8482025
Hawkins P. A., et al. A global genomic perspective on the multidrug-resistant Streptococcus pneumoniae 15A-CC63 sub-lineage following pneumococcal conjugate vaccine introduction. Microb Genom. 9.2023
Satzke, C., Dunne, E. M., Porter, B. D., Klugman, K. P. & Mulholland, E. K. PneuCarriage project group. The PneuCarriage project: a multi-centre comparative study to identify the best serotyping methods for examining pneumococcal carriage in vaccine evaluation studies. PLoS Med. 12, e1001903 (2015).
doi: 10.1371/journal.pmed.1001903 pubmed: 26575033 pmcid: 4648509
Valente, C. et al. Impact of the 13-valent pneumococcal conjugate vaccine on Streptococcus pneumoniae multiple serotype carriage. Vaccine 34, 4072–4078 (2016).
doi: 10.1016/j.vaccine.2016.06.017 pubmed: 27325351
Valente, C. et al. Decrease in pneumococcal co-colonization following vaccination with the seven-valent pneumococcal conjugate vaccine. PLoS ONE 7, e30235 (2012).
doi: 10.1371/journal.pone.0030235 pubmed: 22253924 pmcid: 3257259
Kandasamy, R. et al. Decline in pneumococcal vaccine serotype carriage, multiple-serotype carriage, and carriage density in Nepalese children after PCV10 introduction: A pre-post comparison study. Vaccine, (2024).
Roca, A. et al. Effect of age and vaccination with a pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal carriage. Clin Infect. Dis. 55, 816–824 (2012).
doi: 10.1093/cid/cis554 pubmed: 22700830 pmcid: 3423933
Dorj, G., Hendrie, D., Parsons, R. & Sunderland, B. An evaluation of prescribing practices for community-acquired pneumonia (CAP) in Mongolia. BMC Health Serv. Res. 13, 379 (2013).
doi: 10.1186/1472-6963-13-379 pubmed: 24088338 pmcid: 4016517
Dorj, G. et al. Antibiotic Utilization Trends in Two State Hospitals of Mongolia from 2013 to 2017. BioMed Res. Int. 2019, 9160296 (2019).
doi: 10.1155/2019/9160296
Dorj, G. et al. National surveillance of antibiotic consumption in Mongolia. Int. J. Infect. Dis. 101, 96 (2020).
doi: 10.1016/j.ijid.2020.09.275
Center for Health Development. Health Statistics Information Database: Ministry of Health, Mongolia; 2023. Available from: https://1313.mn/ (Accessed 06 Jan 2023).
Danino, D. et al. Decline in Pneumococcal disease in Young children during the coronavirus disease 2019 (COVID-19) pandemic in Israel associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study. Clin Infect Dis 75, e1154–e1164 (2022).
doi: 10.1093/cid/ciab1014 pubmed: 34904635
Rybak, A. et al. Association of Nonpharmaceutical Interventions During the COVID-19 Pandemic With Invasive Pneumococcal Disease, Pneumococcal Carriage, and Respiratory Viral Infections Among Children in France. JAMA Netw Open 5, e2218959 (2022).
doi: 10.1001/jamanetworkopen.2022.18959 pubmed: 35763298 pmcid: 9240903
Satzke, C. et al. Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. Vaccine 32, 165–179 (2013).
doi: 10.1016/j.vaccine.2013.08.062 pubmed: 24331112
Belman S., et al. Genetic background of Cambodian pneumococcal carriage isolates following pneumococcal conjugate vaccine 13. Microbial Genomics, 8. 2022
Javaid N., et al. Strain features of pneumococcal isolates in the pre- and post-PCV10 era in Pakistan. Microbial Genomics. 2024;10.
La Vincente, S. F. et al. Evaluation of a phased pneumococcal conjugate vaccine introduction in Mongolia using enhanced pneumonia surveillance and community carriage surveys: a study protocol for a prospective observational study and lessons learned. BMC Public Health 19, 333 (2019).
doi: 10.1186/s12889-019-6639-y pubmed: 30898094 pmcid: 6429832
Salter, S. J. et al. Variation at the capsule locus, cps, of mistyped and non-typable Streptococcus pneumoniae isolates. Microbiology 158, 1560–1569 (2012).
doi: 10.1099/mic.0.056580-0 pubmed: 22403189 pmcid: 3541774
Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inf. 95, 103208 (2019).
doi: 10.1016/j.jbi.2019.103208

Auteurs

Claire von Mollendorf (C)

Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Melbourne, Australia. claire.vonmollendorf@mcri.edu.au.
Department of Paediatrics, The University of Melbourne, Melbourne, Australia. claire.vonmollendorf@mcri.edu.au.

Tuya Mungun (T)

National Center of Communicable Diseases, Ulaanbaatar, Mongolia.

Munkhchuluun Ulziibayar (M)

National Center of Communicable Diseases, Ulaanbaatar, Mongolia.

Paige Skoko (P)

Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.
Department of Paediatrics, The University of Melbourne, Melbourne, Australia.

Laura Boelsen (L)

Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.

Cattram Nguyen (C)

Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.
Department of Paediatrics, The University of Melbourne, Melbourne, Australia.

Purevsuren Batsaikhan (P)

National Center of Communicable Diseases, Ulaanbaatar, Mongolia.

Bujinlkham Suuri (B)

National Center of Communicable Diseases, Ulaanbaatar, Mongolia.

Dashtseren Luvsantseren (D)

National Center of Communicable Diseases, Ulaanbaatar, Mongolia.

Dorj Narangerel (D)

Ministry of Health, Ulaanbaatar, Mongolia.

Bilegtsaikhan Tsolmon (B)

National Center of Communicable Diseases, Ulaanbaatar, Mongolia.
Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.

Sodbayar Demberelsuren (S)

Expanded Programme on Immunization, World Health Organization, Ulaanbaatar, Mongolia.

Belinda D Ortika (BD)

Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.

Casey L Pell (CL)

Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.

Ashleigh Wee-Hee (A)

Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.
Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Monica L Nation (ML)

Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.

Jason Hinds (J)

Institute for Infection and Immunity, St George's, University of London, London, UK.
BUGS Bioscience, London Bioscience Innovation Centre, London, UK.

Eileen M Dunne (EM)

Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.
Department of Paediatrics, The University of Melbourne, Melbourne, Australia.

E Kim Mulholland (EK)

Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.
Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
London School of Hygiene and Tropical Medicine, London, UK.

Catherine Satzke (C)

Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.
Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH